Phaseline

Companies › Orion Corporation, Orion Pharma

Orion Corporation, Orion Pharma: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ODM-212
Unclear mechanism
–Phase 1Solid Tumours; MesotheliomaDec 2027
ODM-216–Phase 1Advanced Solid Tumors CancerJan 2028
ODM-208
17α-hydroxylase/17,20-lyase (CYP17A1) inhibitor
–Phase 1Prostate Cancer Metastatic–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03436485ODM-208Phase 1Prostate Cancer MetastaticOncologyOct 2026
NCT06725758ODM-212Phase 1Solid TumoursOncologyDec 2027
NCT07805252ODM-216Phase 1Advanced Solid Tumors CancerOncologyJan 2028
NCT07563738ODM-212Phase 1MesotheliomaOncologySep 2029

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.